doi:10.1136/openhrt-2015-000327
Gesta S, Bluher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, et al
The question facing America isnt simply whether these drugs are the answer to our metabolic crisis, but whether our health care system can meet this moment of transformation with a commitment to finding options affordable for all citizens not just those who can afford to participate in the revolution
Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)
UnitedHealthcare offers optional coverage for GLP-1 medications, primarily targeting clients or businesses that choose to include weight loss products in their plans
But given that the drugs also appear to act on the brains reward system, more direct neurological effects are also plausible